Promising Agents in the Pipeline for CLL Treatment

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, talks about some of the emerging agents in the chronic lymphocytic leukemia treatment landscape.

Transcript

Some of the agents, certainly we’re seeing the CAR T-cell therapy being studied initially, certainly right now in the relapsed/refractory setting but it’s also being used in combination for upfront therapy. There’s a few early trials that were presented at the last ASH meeting and as well as some of the new second- and third-generation PI3 kinase inhibitors that perhaps could provide a more effective, integrative approach in terms of targeting multiple isoforms within different pathways that participate in B-cell malignancy proliferation.